Cerevel Therapeutics Holdings Stock EBITDA
Cerevel Therapeutics Holdings fundamentals help investors to digest information that contributes to Cerevel Therapeutics' financial success or failures. It also enables traders to predict the movement of Cerevel Stock. The fundamental analysis module provides a way to measure Cerevel Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cerevel Therapeutics stock.
Cerevel |
Cerevel Therapeutics Holdings Company EBITDA Analysis
Cerevel Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Cerevel Therapeutics EBITDA | (441.64 M) |
Most of Cerevel Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cerevel Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Cerevel Therapeutics Holdings reported earnings before interest,tax, depreciation and amortization of (441.64 Million). This is 150.33% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 111.33% higher than that of the company.
Cerevel EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cerevel Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cerevel Therapeutics could also be used in its relative valuation, which is a method of valuing Cerevel Therapeutics by comparing valuation metrics of similar companies.Cerevel Therapeutics is currently under evaluation in ebitda category among its peers.
Cerevel Fundamentals
| Return On Equity | -0.92 | |||
| Return On Asset | -0.3 | |||
| Current Valuation | 7.71 B | |||
| Shares Outstanding | 182.2 M | |||
| Shares Owned By Insiders | 15.32 % | |||
| Shares Owned By Institutions | 85.12 % | |||
| Number Of Shares Shorted | 5.98 M | |||
| Price To Earning | (0.26) X | |||
| Price To Book | 14.51 X | |||
| EBITDA | (441.64 M) | |||
| Net Income | (432.84 M) | |||
| Cash And Equivalents | 531.21 M | |||
| Cash Per Share | 3.58 X | |||
| Total Debt | 480.78 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 9.52 X | |||
| Book Value Per Share | 3.10 X | |||
| Cash Flow From Operations | (342.3 M) | |||
| Short Ratio | 2.37 X | |||
| Earnings Per Share | (2.73) X | |||
| Target Price | 43.4 | |||
| Number Of Employees | 355 | |||
| Beta | 1.41 | |||
| Market Capitalization | 8.19 B | |||
| Total Asset | 1.24 B | |||
| Retained Earnings | (1.4 B) | |||
| Working Capital | 914.76 M | |||
| Current Asset | 9.77 M | |||
| Current Liabilities | 5.22 M | |||
| Net Asset | 1.24 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |